Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
2015-1949
Phase 3 small_molecule completed
Quick answer
Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) for Eosinophilic Gastrointestinal Disorders (EGIDs) is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Eosinophilic Gastrointestinal Disorders (EGIDs)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed